Bli medlem
Bli medlem

Du är här

2022-08-17

AroCell AB (publ) Interim Report January 1st to June 30th, 2022

A word from the CEO
”It is with great pleasure that I can state that the positive sales trend continued during the second quarter within our two main segments, oncology and bacteriology. Order intake going forward also looks very good, and it is very satisfying to see that our work is bearing fruit. During the quarter, we validated a new reader for our bladder cancer test and started discussions with Attana AB about managing the production of their consumables in our production facility.”
 
Anders Hultman, CEO
 
Reporting period April 1st – June 30th
·    Net sales amounted to 6,349 (30) KSEK.
·   Profit after financial items amounted to -16,016 (-6,727) KSEK
·   Cash flow from operating activities for the period amounted to -1,397 (-5,185) KSEK
·   Earnings per share before and after dilution amounted to -0.07 (-0.09) SEK
·   Cash and cash equivalents at the end of the period amounted to 69,814 (29,748) KSEK
 
Reporting period January 1st – June 30th
·   Net sales amounted to 14,118 (73) KSEK
·   Profit after financial items amounted to -31,710 (-12,806) KSEK
·   Cash flow from operating activities for the period amounted to -9,517 (-11,421) KSEK
·   Earnings per share before and after dilution amounted to -0.16 (-0.17) SEK
·   Cash and cash equivalents at the end of the period amounted to 69,814 (29,748) KSEK
 
Events during the reporting period April 1st – June 30th
·    Ellen Dittberner was appointed Chief Financial Officer (CFO) as of August. Ellen replaces the current CFO, Lars Jakobsson, who will retire. Ellen has solid experience, which includes driving change and development work.
 
·    AroCell started discussions with Attana AB regarding moving their production of consumables, for example, sensor chips, to AroCell.
 
·    A new evaluation study of the product TUBEX® TF was started in Uganda. This study is being conducted in collaboration with the Uganda National Public Health Laboratory Services (UNHLS), to evaluate TUBEX® TF. Positive study results will form the basis for an application for market approval followed by sales.
 
·    AroCell held the annual general meeting on 24 May 2022.
 
·    AroCell's quantitative point-of-care (POC) for bladder cancer UBC® Rapid was verified for result interpretation on a new instrument, the Cube Reader. By differentiating UBC® Rapid and meeting the different needs of end users, the possibility of more widespread use increases.
 
·    AroCell acquired 1,313,432 shares in the subsidiary IDL Biotech AB during the second quarter through a compulsory redemption of remaining shares. AroCell now owns all shares in IDL Biotech AB.
 
Interim report January 1st – June 30th, 2022 (available in Swedish only) (Link)

Contacts


Anders Hultman, CEO
Phone: +46(0)18 50 30 20
E-mail: anders.hultman@arocell.com

About AroCell


AroCell AB (publ) is a Swedish company that develops and markets blood and urine sample tests. The corporation specializes in oncology and bacteriology. The company has a broad product portfolio, used in healthcare, and established in various markets. In oncology, AroCell uses various biomarkers, TK1, and cytokeratins, to support the treatment of various cancers such as breast, prostate, and bladder cancers. AroCell's product portfolio also includes a rapid bacteriological test for a simple and safe diagnosis of typhoid fever. AroCell (AROC) is listed on Nasdaq First North Growth Market with Redeye AB as company's Certified Adviser. For more information; www.arocell.com

This information is information that AroCell is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2022-08-17 08:00 CEST.

Attachments


AroCell Delårsrapport 2 2022
PM Q2 2022 ENG

Författare MFN